Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
Lyndon P JamesFayette KlaassenSedona SweeneyJennifer FurinMolly F FrankeReza YaesoubiDumitru ChesovNelly CiobanuAlexandru CodreanuValeriu CruduTed CohenNicolas A MenziesPublished in: PLoS medicine (2024)
Compared to standard of care, longer regimens, the implementation of the 6-month BPaLM regimen could improve the cost-effectiveness of care for individuals diagnosed with RR-TB, particularly in settings with a high burden of drug-resistant TB. Further research may be warranted to explore the impact and cost-effectiveness of shorter RR-TB regimens across settings with varied drug-resistant TB burdens and national income levels.
Keyphrases
- drug resistant
- mycobacterium tuberculosis
- quality improvement
- multidrug resistant
- acinetobacter baumannii
- healthcare
- palliative care
- pulmonary tuberculosis
- primary care
- pain management
- mental health
- hiv infected
- pseudomonas aeruginosa
- antiretroviral therapy
- chronic pain
- electronic health record
- health insurance
- hepatitis c virus